logo
  

TCR2 Therapeutics Reports Positive Interim Results From Ongoing Phase 1 Portion Of Gavo-cel Trial

TCR2 Therapeutics Inc. (TCRR) announced positive interim results from the ongoing phase 1 portion of the gavo-cel phase 1/2 clinical trial for mesothelin-expressing solid tumors. The company is very encouraged by the progression free survival and overall survival observed among patients with refractory mesothelioma treated so far with gavo-cel in the phase 1 trial. Gavo-cel was generally well tolerated with a manageable adverse event profile in the study.

The primary objectives of the phase 1 portion of the trial are to define the safety profile of gavo-cel in patients whose tumors overexpress mesothelin and to determine the recommended phase 2 dose. The company said the recommended phase 2 dose is being refined after identification of the maximum tolerated dose.

Alfonso Quintás-Cardama, Chief Medical Officer of TCR2, said: "Based on these data and the most recent patient experiencing a very mild safety profile at a cell dose of 3x108/m2, we believe the identification of the recommended phase 2 dose is close at hand."

Shares of TCR2 Therapeutics were up 4% in pre-market trade on Friday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Royal Caribbean Group's ultra-luxury brand Silversea Cruises is set to launch the world's first hybrid-powered cruise ship in the summer of 2023. This will also be the first ship with large-scale fuel cell technology to enable emission-free port operations. The fuel cells will provide 100% of power while at port. Affco USA is recalling around 24,461 pounds of frozen raw lamb shoulder products that were not presented for import re-inspection into the U.S., the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. The recall involves the frozen raw lamb shoulder items that were imported on July 12, 2021. American Express Company (AXP) reported an increase in profit for the third quarter that also topped Wall Street estimates. Consolidated total revenues net of interest expense rose 25 percent year-on-year, primarily reflecting growth in Card Member spending, as well as a rise in the average discount...
RELATED NEWS
Follow RTT